Skip to main content
Premium Trial:

Request an Annual Quote

MiraiBio, BioSource to Develop Assays Using Luminex Technology

NEW YORK, March 29 – MiraiBio and BioSource International said Thursday they have agreed to jointly develop biological assays for use in drug discovery using Luminex’s LabMAP technology.

BioSource, based in Camarillo, Calif., will develop assay panels related to extracellular signaling, signal transduction, and cytokine research, while MiraiBio, formerly the Genetic Systems Division of Hitachi Software Engineering, will write software to accompany the assays.

The two companies will also combine their marketing, sales, and distribution efforts, and the first assays for cytokine research will become available in April.

"This partnership combines MiraiBio's expertise in laser-based systems and software integration with BioSource's expertise in kit development to provide our customers with the best possible solution," Leonard Klevan, MiraiBio’s president, said in a statement.

Last December, MiraiBio, based in Alameda, Calif., signed a multi-year license for the LabMAP technology from Luminex. The technology uses microspheres, small lasers, digital processors, and software to perform up to 100 assays per drop of fluid.  
The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.